Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Total Non-Current Liabilities (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Total Non-Current Liabilities for 12 consecutive years, with $3.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities rose 1.58% year-over-year to $3.1 million, compared with a TTM value of $3.1 million through Sep 2025, up 1.58%, and an annual FY2024 reading of $5.3 million, up 5.84% over the prior year.
  • Total Non-Current Liabilities was $3.1 million for Q3 2025 at Arcadia Biosciences, down from $3.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $26.0 million in Q2 2021 and bottomed at $3.1 million in Q1 2025.
  • Average Total Non-Current Liabilities over 5 years is $8.3 million, with a median of $6.1 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities tumbled 75.98% in 2022, then soared 79.78% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $10.7 million in 2021, then tumbled by 43.47% to $6.0 million in 2022, then dropped by 16.94% to $5.0 million in 2023, then rose by 5.84% to $5.3 million in 2024, then crashed by 40.67% to $3.1 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for RKDA at $3.1 million in Q3 2025, $3.3 million in Q2 2025, and $3.1 million in Q1 2025.